Overview

Description

  • Nature
    Synthetic

Specifications

Our Abpromise guarantee covers the use of ab12578 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking

  • Form
    Liquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • Cytoskeletal associated protein tyrosine phosphatase
    • MGC126803
    • PEZ
    • Phosphatase with ezrin domain
    • Protein tyrosine phosphatase non receptor type 14
    • Protein tyrosine phosphatase pez
    • Protein-tyrosine phosphatase pez
    • PTN14_HUMAN
    • PTP 36
    • PTP36
    • PTPD 2
    • PTPN 14
    • PTPN14
    • Tyrosine protein phosphatase non receptor type 14
    • Tyrosine-protein phosphatase non-receptor type 14
    see all
  • Function
    Protein tyrosine phosphatase which may play a role in the regulation of lymphangiogenesis.
  • Tissue specificity
    Expressed in a variety of human tissues including kidney, skeletal muscle, lung and placenta.
  • Involvement in disease
    Defects in PTPN14 are a cause of choanal atresia and lymphedema (CHATLY) [MIM:613611]. A disease characterized by posterior choanal atresia and lymphedema. Additional features are a high-arched palate, hypoplastic nipples, and mild pectus excavatum. Note=A homozygous deletion in PTPN14 predicted to result in frameshift and premature truncation, has been shown to be the cause of choanal atresia and lymphedema in one family.
  • Sequence similarities
    Belongs to the protein-tyrosine phosphatase family. Non-receptor class subfamily.
    Contains 1 FERM domain.
    Contains 1 tyrosine-protein phosphatase domain.
  • Post-translational
    modifications
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • Cellular localization
    Cytoplasm > cytoskeleton.
  • Information by UniProt

References

ab12578 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab12578.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up